Cariprazine Hydrochloride Patent Expiration
Cariprazine Hydrochloride is used for treating major depressive disorder, bipolar disorder, and schizophrenia. It was first introduced by Abbvie Inc
Cariprazine Hydrochloride Patents
Given below is the list of patents protecting Cariprazine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vraylar | US7737142 | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists | Sep 17, 2029 | Abbvie |
| Vraylar | USRE47350 | Pharmaceutical formulations containing dopamine receptor ligands | Jul 16, 2029 | Abbvie |
| Vraylar | USRE49110 | Pharmaceutical formulations containing dopamine receptor ligands | Jul 16, 2029 | Abbvie |
| Vraylar | USRE49302 | Pharmaceutical formulations containing dopamine receptor ligands | Jul 16, 2029 | Abbvie |
| Vraylar | US7943621 | Salts of piperazine compounds as D3/D2 antagonists | Dec 16, 2028 | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cariprazine Hydrochloride's patents.
Latest Legal Activities on Cariprazine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Cariprazine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Nov, 2022 | US7943621 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Dec, 2021 | US7737142 |
| Patent Term Extension Certificate Critical | 04 Dec, 2019 | US7737142 |
| Post Issue Communication - Certificate of Correction | 09 Jun, 2019 | US7737142 |
| Mail Certificate of Correction Memo | 05 Jun, 2019 | US7737142 |
| Certificate of Correction Memo | 04 Jun, 2019 | US7737142 |
| Notice of Final Determination -Election Required | 17 Apr, 2019 | US7737142 |
| Notice of Final Determination -Election Required | 17 Apr, 2019 | US7943621 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Nov, 2018 | US7943621 |
| FDA Final Eligibility Letter Critical | 10 Oct, 2018 | US7737142 |
Cariprazine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Cariprazine Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Cariprazine Hydrochloride. The first generic version for Cariprazine Hydrochloride was by Zydus Worldwide Dmcc and was approved on Sep 9, 2022. And the latest generic version is by Sun Pharmaceutical Industries Ltd and was approved on Sep 30, 2022.
Given below is the list of companies who have filed for Cariprazine Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 4 different strengths of generic version for Cariprazine Hydrochloride. Given below are the details of the strengths of this generic introduced by Sun Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 1.5MG BASE | capsule | Discontinued | ORAL | N/A | Sep 30, 2022 |
| EQ 3MG BASE | capsule | Discontinued | ORAL | N/A | Sep 30, 2022 |
| EQ 4.5MG BASE | capsule | Discontinued | ORAL | N/A | Sep 30, 2022 |
| EQ 6MG BASE | capsule | Discontinued | ORAL | N/A | Sep 30, 2022 |
Manufacturing Plant Locations New
Sun Pharm's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Sun Pharm as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||||||||||||
| India |
| |||||||||||||||||||||||||||||
2. ZYDUS
Zydus Worldwide Dmcc has filed for 4 different strengths of generic version for Cariprazine Hydrochloride. Given below are the details of the strengths of this generic introduced by Zydus.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 6MG BASE | capsule | Discontinued | ORAL | N/A | Sep 9, 2022 |
| EQ 1.5MG BASE | capsule | Discontinued | ORAL | N/A | Sep 9, 2022 |
| EQ 3MG BASE | capsule | Discontinued | ORAL | N/A | Sep 9, 2022 |
| EQ 4.5MG BASE | capsule | Discontinued | ORAL | N/A | Sep 9, 2022 |
Manufacturing Plant Locations New
Zydus's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Zydus as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||||||
| United States |
| |||||||||||||||||||||||